{"created":"2021-03-01T06:40:28.155008+00:00","id":34022,"links":{},"metadata":{"_buckets":{"deposit":"4ff357d8-14ad-4df5-8206-1010a0321617"},"_deposit":{"id":"34022","owners":[],"pid":{"revision_id":0,"type":"depid","value":"34022"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00034022","sets":["453:455","471:561:562"]},"item_6_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"9-ING-41(GSK-3阻害剤)は、腎癌に対して単剤および併用療法として有効である"}]},"item_6_date_granted_51":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2020-03-23"}]},"item_6_degree_grantor_49":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"新潟大学"}]}]},"item_6_degree_name_48":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士(医学)"}]},"item_6_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological　processes including cancer. GSK-3 has two isoforms, GSK-3αand GSK-3β, and GSK-3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aimed to investigate the antitumor effects of9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3β inhibitor active in patients with advanced cancer. In renal cancer cell lines, treatment with 9-ING-41 alone induced cell cycle arrest and apoptosis, and autophagy inhibitors increased the antitumor effects of 9-ING-41 when used in combination. Treatment with 9-ING-41 potentiated the antitumor effects of targeted therapeutics and increased the cytotoxic effects of cytokine-activated immune cells on renal cancer cell lines. These results provided a compelling rationale for the inclusion of patients with renal cancer in studies of 9-ING-41, both as a single agent and in combination with current standard therapies.","subitem_description_type":"Abstract"}]},"item_6_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"International Journal of Molecular Medicine. 2020, 45(2), 315-323.","subitem_description_type":"Other"}]},"item_6_description_53":{"attribute_name":"学位記番号","attribute_value_mlt":[{"subitem_description":"新大院博(医)甲第931号","subitem_description_type":"Other"}]},"item_6_dissertation_number_52":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"13101甲第4697号"}]},"item_6_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"178044","nameIdentifierScheme":"WEKO"}],"names":[{"name":"安楽, 力"}]}]},"item_6_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"info:doi/10.3892/ijmm.2019.4427","subitem_relation_type_select":"DOI"}}]},"item_6_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"ETD"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Anraku, Tsutomu"}],"nameIdentifiers":[{"nameIdentifier":"178043","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-31"}],"displaytype":"detail","filename":"r1nmk931.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"本文","url":"https://niigata-u.repo.nii.ac.jp/record/34022/files/r1nmk931.pdf"},"version_id":"3771a466-ccb2-4a7b-87a2-dfbb03d77397"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-31"}],"displaytype":"detail","filename":"r1nmk931_a.pdf","filesize":[{"value":"571.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"要旨","url":"https://niigata-u.repo.nii.ac.jp/record/34022/files/r1nmk931_a.pdf"},"version_id":"32faba86-9383-4f9d-87cc-578abae0acb4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"glycogen synthase kinase-3","subitem_subject_scheme":"Other"},{"subitem_subject":"renal cell carcinoma","subitem_subject_scheme":"Other"},{"subitem_subject":"apoptosis","subitem_subject_scheme":"Other"},{"subitem_subject":"cell cycle arrest","subitem_subject_scheme":"Other"},{"subitem_subject":"immune cells","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"thesis","resourceuri":"http://purl.org/coar/resource_type/c_46ec"}]},"item_title":"Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer"}]},"item_type_id":"6","owner":"1","path":["455","562"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-08-31"},"publish_date":"2020-08-31","publish_status":"0","recid":"34022","relation_version_is_last":true,"title":["Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T04:04:20.813661+00:00"}